These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 35120943)
1. Shikonin impedes phase separation and aggregation of tau and protects SH-SY5Y cells from the toxic effects of tau oligomers. Venkatramani A; Mukherjee S; Kumari A; Panda D Int J Biol Macromol; 2022 Apr; 204():19-33. PubMed ID: 35120943 [TBL] [Abstract][Full Text] [Related]
2. C1 Inhibits Liquid-Liquid Phase Separation and Oligomerization of Tau and Protects Neuroblastoma Cells against Toxic Tau Oligomers. Pradhan A; Mishra S; Surolia A; Panda D ACS Chem Neurosci; 2021 Jun; 12(11):1989-2002. PubMed ID: 34008959 [TBL] [Abstract][Full Text] [Related]
3. EB1 Increases the Dynamics of Tau Droplets and Inhibits Tau Aggregation: Implications in Tauopathies. Venkatramani A; Ashtam A; Panda D ACS Chem Neurosci; 2024 Mar; 15(6):1219-1233. PubMed ID: 38445984 [TBL] [Abstract][Full Text] [Related]
4. Contrasting Effects of Ferric and Ferrous Ions on Oligomerization and Droplet Formation of Tau: Implications in Tauopathies and Neurodegeneration. Mukherjee S; Panda D ACS Chem Neurosci; 2021 Dec; 12(23):4393-4405. PubMed ID: 34783530 [TBL] [Abstract][Full Text] [Related]
5. Pathological concentration of zinc dramatically accelerates abnormal aggregation of full-length human Tau and thereby significantly increases Tau toxicity in neuronal cells. Hu JY; Zhang DL; Liu XL; Li XS; Cheng XQ; Chen J; Du HN; Liang Y Biochim Biophys Acta Mol Basis Dis; 2017 Feb; 1863(2):414-427. PubMed ID: 27890528 [TBL] [Abstract][Full Text] [Related]
6. Curcumin Inhibits Tau Aggregation and Disintegrates Preformed Tau Filaments in vitro. Rane JS; Bhaumik P; Panda D J Alzheimers Dis; 2017; 60(3):999-1014. PubMed ID: 28984591 [TBL] [Abstract][Full Text] [Related]
7. The FK506-binding protein FKBP52 in vitro induces aggregation of truncated Tau forms with prion-like behavior. Giustiniani J; Guillemeau K; Dounane O; Sardin E; Huvent I; Schmitt A; Hamdane M; Buée L; Landrieu I; Lippens G; Baulieu EE; Chambraud B FASEB J; 2015 Aug; 29(8):3171-81. PubMed ID: 25888602 [TBL] [Abstract][Full Text] [Related]
8. Purification and Characterization of Low-n Tau Oligomers. Kaniyappan S; Chandupatla RR; Mandelkow E Methods Mol Biol; 2018; 1779():99-111. PubMed ID: 29886530 [TBL] [Abstract][Full Text] [Related]
9. Neurotoxicity of oligomers of phosphorylated Tau protein carrying tauopathy-associated mutation is inhibited by prion protein. Nieznanska H; Boyko S; Dec R; Redowicz MJ; Dzwolak W; Nieznanski K Biochim Biophys Acta Mol Basis Dis; 2021 Nov; 1867(11):166209. PubMed ID: 34246750 [TBL] [Abstract][Full Text] [Related]
10. Naphthoquinone-Tryptophan Hybrid Inhibits Aggregation of the Tau-Derived Peptide PHF6 and Reduces Neurotoxicity. Frenkel-Pinter M; Tal S; Scherzer-Attali R; Abu-Hussien M; Alyagor I; Eisenbaum T; Gazit E; Segal D J Alzheimers Dis; 2016; 51(1):165-78. PubMed ID: 26836184 [TBL] [Abstract][Full Text] [Related]
11. Targeting the ensemble of heterogeneous tau oligomers in cells: A novel small molecule screening platform for tauopathies. Lo CH; Lim CK; Ding Z; Wickramasinghe SP; Braun AR; Ashe KH; Rhoades E; Thomas DD; Sachs JN Alzheimers Dement; 2019 Nov; 15(11):1489-1502. PubMed ID: 31653529 [TBL] [Abstract][Full Text] [Related]
12. Human tauopathy-derived tau strains determine the substrates recruited for templated amplification. Tarutani A; Miyata H; Nonaka T; Hasegawa K; Yoshida M; Saito Y; Murayama S; Robinson AC; Mann DMA; Tomita T; Hasegawa M Brain; 2021 Sep; 144(8):2333-2348. PubMed ID: 33693528 [TBL] [Abstract][Full Text] [Related]
13. Modulating disease-relevant tau oligomeric strains by small molecules. Lo Cascio F; Garcia S; Montalbano M; Puangmalai N; McAllen S; Pace A; Palumbo Piccionello A; Kayed R J Biol Chem; 2020 Oct; 295(44):14807-14825. PubMed ID: 32737202 [TBL] [Abstract][Full Text] [Related]
14. Prolonged nitric oxide treatment induces tau aggregation in SH-SY5Y cells. Takahashi M; Chin Y; Nonaka T; Hasegawa M; Watanabe N; Arai T Neurosci Lett; 2012 Feb; 510(1):48-52. PubMed ID: 22249117 [TBL] [Abstract][Full Text] [Related]
15. Tau liquid-liquid phase separation: At the crossroads of tau physiology and tauopathy. Islam M; Shen F; Regmi D; Petersen K; Karim MRU; Du D J Cell Physiol; 2024 Jun; 239(6):e30853. PubMed ID: 35980344 [TBL] [Abstract][Full Text] [Related]
16. Azure C Targets and Modulates Toxic Tau Oligomers. Lo Cascio F; Kayed R ACS Chem Neurosci; 2018 Jun; 9(6):1317-1326. PubMed ID: 29378132 [TBL] [Abstract][Full Text] [Related]
17. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies. Navarrete LP; Pérez P; Morales I; Maccioni RB Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038 [TBL] [Abstract][Full Text] [Related]
18. Functional Applications of Stable Tau Oligomers in Cell Biology and Electrophysiology Studies. Hill E; Moffat KG; Wall MJ; Zetterberg H; Blennow K; Karikari TK Methods Mol Biol; 2023; 2551():147-161. PubMed ID: 36310202 [TBL] [Abstract][Full Text] [Related]
19. SH-SY5Y-derived neurons: a human neuronal model system for investigating TAU sorting and neuronal subtype-specific TAU vulnerability. Bell M; Zempel H Rev Neurosci; 2022 Jan; 33(1):1-15. PubMed ID: 33866701 [TBL] [Abstract][Full Text] [Related]